In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
Others have stated their priorities directly with Federal Government. Through these interviews, AHJ gives a final opportunity to communicate to all health stakeholders, the funding needs for a range of priorities. These range from new models of care to pilots and wholesale, system improvements to building more sustainable workforces to help grow certain sectors of the health system
The Chief Executive Officer of Australian College of Nursing, Adjunct Professor Kylie Ward FACN spoke in depth with Australian Health Journal about:
- The key recommendations in ACN’s pre-budget submission to Federal Government
- The impact of legislation requiring a Registered Nurse (RN) at every residential aged care facility from 1st July 2023
- Why scholarships in nursing leadership are important
- Why ACN has recommended the Government fund 200 Pacific nurses in 15 nations for the online ACN postgraduate certification
- The need for a multi-pronged approach that includes skilled migration in rebuilding the nursing workforce
-
Scott Willis, talks Physiotherapy
Health Executive Leadership Insights (HELI)
Scott Willis, the National President of the Australian Physiotherapy Association talks Physiotherapy -
Value of MedTech Report brings Industry and Government together
In June 2023 the Medical Technology Association of Australia (MTAA) launched The Value of MedTech Report – a major study quantifying the difference the MedTech industry makes to the lives of Australian patients, the healthcare system and the Australian economy.
Australian Health Journal spoke with MTAA CEO, Ian Burgess and MTAA Policy Manager, Pravin Siriwardena about the report and its key findings.
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
